AI-generated · cited to primary sources · not investment advice
Moderna, Inc. (MRNA) Mar 2025 Filing Analysis
Where does growth come from?
Other revenue appeared as a meaningful new revenue stream in Q1 FY25, reaching $22 million versus none reported in Q1 FY24. It included $8 million of licensing and royalty revenue and $12 million of other revenue, including government-supported manufacturing readiness arrangements. The latest filing supports a new, diversified revenue source but not yet a multi-quarter growth rate. (1 new trend, 1 steady across 2 signals)
“Other revenue increased by $22 million, or 100%, for the three months ended March 31, 2025, compared to the same period in 2024. The increase for the three and three months ended was mainly due to an increase in licensing and royalty and other revenue.”
Moderna continues investing in internal manufacturing capacity, with property, plant and equipment rising modestly to $2.212 billion from $2.196 billion and construction in progress reaching $1.078 billion. However, current-quarter utilization was weak: $21 million of unused-capacity and wind-down costs were recorded, and $42 million of inventory write-downs were primarily linked to excess COVID inventory. Capacity is expanding, but near-term productivity and utilization remain unfavorable. (1 decelerating, 1 new trend across 2 signals)
“Cost of sales for the three months ended March 31, 2025 was $90 million, which included ... inventory write-downs of $42 million, primarily related to our finished and semi-finished COVID vaccine inventory and certain raw materials, unutilized manufacturing capacity and wind-down costs of $21 million, and losses on firm purchase commitments of $10 million. These charges ... were largely driven by customer demand forecast adjustments and commitments related to manufacturing capacity.”
See the full cited Future Growth analysis of Moderna, Inc.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.